Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 11/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | NPY1R | P25929 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22668964 | 0.93 | ATF4 (0.42) | ATF4 | |
| SCHEMBL22669121 | 0.93 | ATF4 (0.42) | ATF4 | |
| SCHEMBL22669126 | 0.93 | MAPK1 (0.39) | RAB9AMAPTMAPK1MEN1KMT2A | |
| SCHEMBL20999255 | 0.92 | ATF4 (0.43) | ATF4RAB9AMAPK1FFAR1MEN1 | |
| SCHEMBL22669232 | 0.91 | ATF4 (0.43) | ATF4RAB9AMAPTMEN1KMT2A | |
| SCHEMBL22669227 | 0.88 | ATF4 (0.44) | ATF4MEN1KMT2A | |
| SCHEMBL22669513 | 0.88 | ATF4 (0.44) | ATF4 | |
| SCHEMBL22669335 | 0.87 | MAOA (0.36) | ATF4MAPTMAPK1MEN1KMT2A | |
| SCHEMBL19569215 | 0.86 | ATF4 (0.57) | ATF4RAB9AMEN1KMT2A | |
| SCHEMBL20999211 | 0.85 | ATF4 (0.42) | ATF4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200361941-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361941-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ATF4 1/4885RAB9A 2904/4885MAPT 3293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.